CDF figures a welcome relief for UK health bosses

30 January 2018

The UK’s first stab at creating a Cancer Drugs Fund (CDF), to give patients access to oncology treatments not available on the National Health Service (NHS), became unsustainable after the Department of Health overspent the fund’s £480 million ($678 million) budget for two years between 2013 and 2015 by £167 million.

This led to the launch of a revamped CDF in July 2016, and NHS bosses who are under ever-increasing pressure to deliver drugs and services while controlling costs, will be relieved to see some early indications of its success.

"Tough negotiations and flexibility are leading to more deals with pharmaceutical companies"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK